Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy

被引:56
作者
Hatano, H
Miller, KD
Yoder, CP
Yanovski, JA
Sebring, NG
Jones, EC
Davey, RT
机构
[1] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA
[2] NICHHD, Dept Crit Care Med, NIH, Bethesda, MD 20892 USA
[3] NICHHD, Dept Nutr, NIH, Bethesda, MD 20892 USA
[4] NICHHD, Dept Radiol, Warren Grant Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA
[5] NICHHD, Unit Growth & Obes, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA
关键词
metabolic abnormalities; hyperlipidemia; hypercholesterolemia; insulin resistance; fat redistribution; lipodystrophy; lipohypertrophy; lipoatrophy; HAART; antiretroviral therapy;
D O I
10.1097/00002030-200009080-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: HAART has been associated with metabolic abnormalities (hyperlipidemia, insulin resistance, alterations in cortisol metabolism) and fat redistribution. Setting: A prospective study of 26 Caucasian men (median age 43.5 years) with HIV-1 viral loads < 500 copies/ml for 12 months while on highly active antiretroviral therapy (HAART) who interrupted treatment for a median of 7.0 weeks (range 4.9-10.3 weeks). Seventeen (65.4%) patients reported at least one fat redistribution symptom at baseline. Method: Serum lipids, glucose and insulin levels during an oral glucose tolerance test, 24-h urinary free cortisol and 17-hydroxycorticosteroids, and anthropometric parameters were measured before HAART cessation and prior to its reinstitution. Results: When baseline values were compared with those obtained after HAART interruption (means +/- SD), there was a significant decrease in total cholesterol (194 +/- 47.3 versus 159 +/- 29.3 mg/dl; P < 0.0001), low density lipoprotein (LDL) cholesterol (114 +/- 32.6 versus 96 +/- 24.7 mg/dl; P = 0.0013), triglycerides (261 +/- 244.3 versus 185 +/- 165.4 mg/dl; P= 0.008), and 24-hour urinary 17-hydroxycorticosteroids (15 +/- 7.9 versus 5 +/- 2.5 mg/24 h, P < 0.0001) and a significant increase in 24-hour urinary free cortisol (45 +/- 34.1 versus 62 +/- 32.2 mu g/24 h; P = 0.016). There were no significant changes in glucose or insulin levels or in anthropometric measurements. Conclusions: A relatively brief interruption of HAART resulted in significant improvements in total cholesterol, LDL cholesterol, and triglyceride levels. No changes were observed in insulin resistance profiles or anthropometric measurements, perhaps because of the brief duration of HAART interruption. These results suggest that hyperlipidemia and alterations in corticosteroid metabolism in the setting of HAART are a direct drug effect that reverses with drug withdrawal. However, glucose metabolism and fat redistribution do not change over the short term. (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:1935 / 1942
页数:8
相关论文
共 40 条
[1]   THE METYRAPONE AND DEXAMETHASONE SUPPRESSION TESTS FOR THE DIFFERENTIAL-DIAGNOSIS OF THE ADRENOCORTICOTROPIN-DEPENDENT CUSHING SYNDROME - A COMPARISON [J].
AVGERINOS, PC ;
YANOVSKI, JA ;
OLDFIELD, EH ;
NIEMAN, LK ;
CUTLER, GB .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (05) :318-327
[2]   Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors [J].
Behrens, G ;
Dejam, A ;
Schmidt, H ;
Balks, HJ ;
Brabant, G ;
Körner, T ;
Stoll, M ;
Schmidt, RE .
AIDS, 1999, 13 (10) :F63-F70
[3]   Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy [J].
Brinkman, K ;
Smeitink, JA ;
Romijn, JA ;
Reiss, P .
LANCET, 1999, 354 (9184) :1112-1115
[4]   COMBINED EFFECTS OF HDL CHOLESTEROL, TRIGLYCERIDE, AND TOTAL CHOLESTEROL CONCENTRATIONS ON 18-YEAR RISK OF ATHEROSCLEROTIC DISEASE [J].
BURCHFIEL, CM ;
LAWS, A ;
BENFANTE, R ;
GOLDBERG, RJ ;
HWANG, LJ ;
CHIU, D ;
RODRIGUEZ, BL ;
CURB, JD ;
SHARP, DS .
CIRCULATION, 1995, 92 (06) :1430-1436
[5]   Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[6]   A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors [J].
Carr, A ;
Samaras, K ;
Burton, S ;
Law, M ;
Freund, J ;
Chisholm, DJ ;
Cooper, DA .
AIDS, 1998, 12 (07) :F51-F58
[7]   A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome [J].
Carr, A ;
Miller, J ;
Law, M ;
Cooper, DA .
AIDS, 2000, 14 (03) :F25-F32
[8]   Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance [J].
Carr, A ;
Samaras, K ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1998, 351 (9119) :1881-1883
[9]   Declining HIV/AIDS mortality in New York City [J].
Chiasson, MA ;
Berenson, L ;
Li, WH ;
Schwartz, S ;
Singh, T ;
Forlenza, S ;
Mojica, BA ;
Hamburg, MA .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (01) :59-64
[10]   Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations [J].
Christeff, N ;
Melchior, JC ;
de Truchis, P ;
Perronne, C ;
Nunez, EA ;
Gougeon, ML .
AIDS, 1999, 13 (16) :2251-2260